India's Jubilant Ingrevia rises after USFDA inspection ends
** Shares of Jubilant Ingrevia JUBN.NS rise as much as
2.4% to 529 rupees, last up 1%
** The specialty chemicals maker gets establishment
inspection report from U.S. Food and Drug Administration
(USFDA), concluded with zero 483 observations for its
manufacturing facility in Gujarat
** JUBN down ~2% so far this week, set to snap three-week
gaining streak
** Stock up ~3% YTD, had fallen 3.8% in 2023- its second
straight year of losses
(Reporting by Dimpal Gulwani in Bengaluru)
((dimpal.gulwani@thomsonreuters.com))
Recent news on Jubilant Ingrevia
See all newsBrief: Jubilant Ingrevia Says Board Approves Acquisition Of 40% Strategic Equity Stake In Zettaone Through Subsidiary
India's Jubilant Ingrevia rises as Kotak sees growth outweighing contract risks
Brief: Jubilant Ingrevia To Buy 40% Stake In Zettaone Technologies India For 1.89 Billion Rupees
Brief: Jubilant Ingrevia June-Quarter Consol Net Profit 1.06 Billion Rupees
Brief: Jubilant Ingrevia March-Quarter Consol Net Profit 864.4 Million Rupees